Does Enclomiphene Affect Fertility?

Fertility and testosterone

Male fertility depends on a signalling loop rather than a single hormone. The hypothalamus releases GnRH, the pituitary responds with luteinising hormone (LH) and follicle-stimulating hormone (FSH), and those two gonadotropins instruct the testes to produce testosterone and to support spermatogenesis. Anything that quiets that signal tends to quiet sperm production with it.

This is the reason the fertility question comes up so often. Men are frequently told that raising testosterone is straightforward, and in one narrow sense it is — but how testosterone is raised determines what happens to the rest of the axis. Two therapies can move the same number on a lab report and have opposite effects on the testes.

Why exogenous testosterone suppresses the axis

When testosterone is introduced from outside the body, the hypothalamus and pituitary read the circulating level as sufficient and reduce their own output. LH and FSH fall. Intratesticular testosterone — the concentration that actually matters for spermatogenesis — falls with them, even while serum testosterone looks healthy.[4]

How enclomiphene works

Enclomiphene citrate is the trans-isomer of clomiphene, a selective estrogen receptor modulator. It occupies estrogen receptors in the hypothalamus, blunting the negative feedback that oestradiol normally exerts there. The hypothalamus reads less oestrogenic signal, GnRH output rises, and the pituitary follows with more LH and FSH.[2]

1. 01Estrogen receptors in the hypothalamus are blocked, reducing negative feedback.
2. 02GnRH pulse frequency and amplitude increase.
3. 03The pituitary releases more LH and FSH into circulation.
4. 04Leydig cells respond with increased endogenous testosterone; Sertoli cell support for spermatogenesis is maintained.

The practical consequence is that the testes remain part of the process. Testosterone production is stimulated rather than substituted, which is why the drug is discussed at all in a fertility context.

A note on terminology

Clomiphene citrate is a mixture of two isomers: enclomiphene and zuclomiphene. Zuclomiphene has a longer half-life and more oestrogenic activity. Enclomiphene is the isolated anti-oestrogenic isomer, which is why the two are not interchangeable in the literature. See the enclomiphene treatment profile for the full pharmacology.

Sperm production

Spermatogenesis is slow. A full cycle takes approximately 64 to 72 days, with further time for epididymal transit, which is why semen parameters are conventionally reassessed on roughly a three-month interval rather than weekly.[4] Hormone levels can change within days; semen analysis cannot.

• Concentration — sperm per millilitre of ejaculate, the parameter most often reported in the enclomiphene literature.
• Motility — the proportion moving progressively.
• Morphology — the proportion with normal form.
• Volume — total ejaculate, which varies substantially between samples from the same man.

What the research shows

The most frequently cited comparison is a randomised study of obese men with secondary hypogonadism, in which enclomiphene was measured against topical testosterone. Both arms raised serum testosterone. Only the enclomiphene arm raised LH and FSH, and sperm concentration behaved differently between the two.[1]

Enclomiphene vs TRT

Both approaches address low testosterone; they are not substitutes for one another. Testosterone replacement is well established, tightly titratable, and appropriate for many men — including men with primary testicular failure, where stimulating the pituitary would achieve nothing. Enclomiphene depends on a testis that can still respond.

Clinicians should discuss the potential effect of testosterone therapy on spermatogenesis with men who are considering fertility.

Endocrine Society, clinical practice guideline

The choice is therefore diagnostic rather than preferential. It depends on where the deficiency originates, what the gonadotropins are doing at baseline, and whether fertility is a stated priority.[5]

Clinical considerations

Enclomiphene is not FDA-approved for male hypogonadism or for infertility. Prescribing it for either is an off-label clinical judgement, made with a specific patient in front of the clinician.

• Fertility intent should be raised at the first consultation, not after therapy begins.
• Oestradiol rises on SERM therapy in some men and is monitored rather than assumed benign.
• Visual disturbance is a recognised class effect of SERMs and warrants prompt review.
• Therapy is reassessed on a defined interval; continuation is not automatic.